GH Dec 2025 20.000 call
| Previous close | 13.00 |
| Open | 13.00 |
| Bid | 11.90 |
| Ask | 13.80 |
| Strike | 20.00 |
| Expiry date | 2025-12-19 |
| Day's range | 13.00 - 13.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 17 |
Business WireGuardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials
PALO ALTO, Calif., June 03, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced its research collaborators from Washington University’s Siteman Cancer Center will lead an oral presentation today at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting highlighting the potential role of liquid biopsy in addressing racial inequities in enrollment in clinical trials and in the use of targeted therapies for advanced breast cancer.
Business WireGuardant Health Named to TIME100 Most Influential Companies
PALO ALTO, Calif., May 31, 2024--Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced its inclusion in the fourth-annual TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world.
Business WireGuardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
PALO ALTO, Calif., May 30, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from 16 studies highlighting the role of Guardant blood tests and real-world data in advancing precision oncology and cancer screening at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, May 31-June 4 in Chicago.
